IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VALENTI, LUCA VITTORIO CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 42.685
EU - Europa 40.271
NA - Nord America 35.566
SA - Sud America 4.376
AF - Africa 875
OC - Oceania 427
Continente sconosciuto - Info sul continente non disponibili 33
Totale 124.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.488
CN - Cina 16.359
GB - Regno Unito 11.474
SG - Singapore 8.739
IT - Italia 8.327
DE - Germania 5.462
HK - Hong Kong 3.217
BR - Brasile 3.025
RU - Federazione Russa 2.972
BD - Bangladesh 2.810
SE - Svezia 2.633
VN - Vietnam 2.238
IN - India 1.968
FR - Francia 1.742
JP - Giappone 1.630
TR - Turchia 1.575
NL - Olanda 1.427
FI - Finlandia 1.099
KR - Corea 1.077
CA - Canada 985
IE - Irlanda 886
ES - Italia 805
MX - Messico 787
ID - Indonesia 703
UA - Ucraina 691
PL - Polonia 552
TW - Taiwan 543
AU - Australia 404
CO - Colombia 381
AR - Argentina 334
BE - Belgio 292
DK - Danimarca 282
GR - Grecia 279
AT - Austria 270
EU - Europa 245
EG - Egitto 224
CH - Svizzera 202
TH - Thailandia 198
IR - Iran 197
PK - Pakistan 193
CL - Cile 191
CI - Costa d'Avorio 167
RO - Romania 164
IQ - Iraq 156
PT - Portogallo 150
PE - Perù 147
SA - Arabia Saudita 125
EC - Ecuador 123
IL - Israele 121
MY - Malesia 113
PH - Filippine 107
ZA - Sudafrica 106
VE - Venezuela 79
UZ - Uzbekistan 77
CZ - Repubblica Ceca 76
DZ - Algeria 76
HU - Ungheria 66
AE - Emirati Arabi Uniti 60
BG - Bulgaria 54
NO - Norvegia 54
MA - Marocco 53
JO - Giordania 52
RS - Serbia 50
CR - Costa Rica 46
KZ - Kazakistan 41
TN - Tunisia 41
KE - Kenya 40
LT - Lituania 38
HR - Croazia 37
NP - Nepal 37
JM - Giamaica 36
LK - Sri Lanka 36
BO - Bolivia 35
SI - Slovenia 35
PA - Panama 33
SK - Slovacchia (Repubblica Slovacca) 31
PY - Paraguay 30
UY - Uruguay 28
AZ - Azerbaigian 26
HN - Honduras 26
MN - Mongolia 26
MM - Myanmar 25
LU - Lussemburgo 24
ET - Etiopia 23
GT - Guatemala 23
NZ - Nuova Zelanda 23
PR - Porto Rico 23
SY - Repubblica araba siriana 23
LB - Libano 22
DO - Repubblica Dominicana 21
MO - Macao, regione amministrativa speciale della Cina 21
GE - Georgia 20
NI - Nicaragua 20
SN - Senegal 20
NG - Nigeria 19
OM - Oman 19
QA - Qatar 19
KW - Kuwait 18
BY - Bielorussia 16
LV - Lettonia 16
Totale 124.099
Salva come PNG Salva come JPEG
Città #
Southend 10.030
Singapore 5.026
Ashburn 3.346
Hong Kong 2.608
Houston 2.354
Milan 2.186
Beijing 2.096
San Jose 2.005
Chandler 1.719
Dallas 1.683
Council Bluffs 1.419
Hanover 1.372
Seattle 1.252
Frankfurt am Main 1.079
Los Angeles 1.037
Fairfield 1.011
Shanghai 915
Princeton 897
Wilmington 876
Dublin 859
New York 841
Hefei 743
Guangzhou 723
Ho Chi Minh City 715
Nanjing 673
Santa Clara 669
Istanbul 594
Bengaluru 593
Helsinki 591
Ann Arbor 587
Tokyo 562
Woodbridge 526
Hanoi 519
Munich 519
Lauterbourg 518
Dearborn 503
Moscow 487
Buffalo 475
Cambridge 473
Rome 468
Hangzhou 460
Jacksonville 448
Jakarta 422
Boardman 409
Toronto 406
São Paulo 380
Redwood City 365
Warsaw 322
Des Moines 314
Redmond 272
Mountain View 270
Tianjin 261
Wuhan 254
Chengdu 248
Seoul 246
The Dalles 238
Chicago 237
Phoenix 230
Changsha 226
Taipei 224
Shenyang 223
Bogotá 214
Andover 213
Jinan 204
Columbus 203
Berlin 197
Shenzhen 197
Amsterdam 187
Nuremberg 185
Serra 185
Naples 173
Sakarya 171
London 170
Cangzhou 168
Fuzhou 167
Abidjan 165
Somerville 163
Atlanta 160
Chongqing 154
Madrid 149
Turin 148
Paris 139
Melbourne 136
Nanchang 135
Ankara 131
Vienna 131
Rio de Janeiro 130
San Diego 130
Mumbai 128
Bari 122
Montreal 121
Zhengzhou 119
Bologna 118
Grafing 117
Brussels 113
Eitensheim 113
Santiago 113
Mexico City 112
Boston 111
Athens 109
Totale 67.905
Salva come PNG Salva come JPEG
Nome #
A multisociety Delphi consensus statement on new fatty liver disease nomenclature 6.467
A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement 4.153
Nonalcoholic Fatty Liver Disease in Children 3.695
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) 2.084
PNPLA3 as a therapeutic target for fatty liver disease : the evidence to date 2.067
The first MASH drug therapy on the horizon: Current perspectives of resmetirom 1.790
Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic Fatty liver disease 1.647
A second update on mapping the human genetic architecture of COVID-19 1.514
Mapping the human genetic architecture of COVID-19 1.169
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease 1.089
COVID-19 and liver disease 868
Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease 708
Statin use and nonalcoholic steatohepatitis in at risk individuals 693
Iron biology 633
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 628
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 626
The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development : a potential therapeutic target? 618
The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease 573
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis 549
Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3 513
Hepcidin levels in chronic hemodialysis patients : A critical evaluation 511
Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers 474
Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma 474
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation 451
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 442
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 432
Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial 426
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 411
HFE mutations and iron in hemodialysis patients 408
Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver 408
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 406
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 391
PNPLA3 I148M polymorphism and progressive liver disease 389
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study 383
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 382
Benzodiazepines induce hyperglycemia in rats by affecting peripheral disposal of glucose 380
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models 376
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy 368
DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE: SYNERGY WITH OBESITY IN INDUCING SYSTEMIC INSULIN RESISTANCE 356
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 356
Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction 355
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression : An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 338
Adiponectin in nonalcoholic fatty liver disease : correlation with liver damage and PNPLA3 genotype 333
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis 330
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 323
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 321
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease 321
Epicardial Adipose Tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease 319
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 317
Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker 316
Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease 315
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 314
High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload 313
The rs2294918 E434K variant modulates PNPLA3 expression and liver damage 313
Complement activation and endothelial perturbation parallel COVID-19 severity and activity 313
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 312
Preliminary evidences of safety and efficacy of flavonoids- and omega 3-based compound for muscular dystrophies treatment: a randomized double-blind placebo controlled pilot clinical trial. 311
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients with Nonalcoholic Fatty Liver Disease 310
β-Klotho gene variation is associated with liver damage in children with NAFLD 309
Response of an Italian reference institute to research challenges regarding a new pandemic: COVID-19 network 308
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients 307
Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis 306
A 360-degree overview of paediatric NAFLD: Recent insights 298
Iron stores, hepcidin, and aortic stiffness in individuals with hypertension 298
The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload 297
Hepatic estrogen receptor alpha drives masculinization in post-menopausal women with metabolic dysfunction-associated steatotic liver disease 295
Effetti della somministrazione di benzodiazepine all’induzione dell’anestesia sulla glicemia plasmatica: studio sperimentale animale 295
PNPLA3 I148M polymorphism, etiology, and clinical features of hepatocellular carcinoma 295
The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls 294
DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY IN INDUCING SYSTEMIC INSULIN RESISTANCE 291
Adiponectin in nonalcoholic fatty liver disease : correlation with liver damage and PNPLA3 genotype 290
Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention 288
Adiponectin in nonalcoholic fatty liver disease : correlation with liver damage and PNPLA3 genotype 288
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis 287
The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease 286
Global Burden of Major Chronic Liver Diseases in 2021 282
Staphylococcus haemolyticus superinfection of Legionella pneumonia during infliximab therapy 280
Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations 278
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy 278
Carotid artery intima-media thickness in nonalcoholic fatty liver disease 277
Iron overload impairs the migratory ability of a model of immature and migratory GnRH neurons 274
The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients : TMPRSS6 and hepcidin in hemodialysis 273
Liver fat accumulation is associated with circulating PCSK9 levels 272
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 271
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity 270
Homozygosity for the PNPLA3/Adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease 270
Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology 269
Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance 267
Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease 266
Acquired hepatocerebral degeneration (AHD) : a peculiar neurological impairment in advanced chronic liver disease 264
MAFLD vs NAFLD : let the contest begin! 264
α1-Antitrypsin mutations in NAFLD : high prevalence and association with altered iron metabolism but not with liver damage 262
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease 261
DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis 261
PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes 258
Emergency Lung Transplantation after {COVID}-19: Immunopathological Insights on Two Affected Patients 258
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women 256
Variables significantly associated with non alcoholic steatohepatitis (NASH) and fibrosis in patients with non alcoholic fatty liver disease (NAFLD) 254
Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up 252
Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease : a case control study 251
Totale 57.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 313.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 313.445
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021724 0 0 0 0 0 0 0 0 0 0 0 724
2021/20228.822 641 432 568 828 738 706 782 669 1.001 698 641 1.118
2022/20238.035 900 738 668 720 864 1.386 307 558 803 190 487 414
2023/20248.119 436 653 425 532 1.529 530 576 469 324 519 936 1.190
2024/202523.524 1.202 1.943 951 1.982 1.661 1.402 1.364 2.259 1.871 2.309 2.501 4.079
2025/202646.072 4.058 3.240 4.736 3.612 3.783 2.901 4.820 2.789 4.651 3.393 4.933 3.156
Totale 128.733